Ron Howell, CEO and president of HST Global, said: “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community.
“We want to ensure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.”